metastatic/advanced - colorectal cancer (mCRC) | |
mCRC - 1st line (L1) | |
atezolizumab plus FOLFOXIRI plus bevacizumab | AtezoTRIBE |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -